Clay B Siegall has bought stock on 9 days since May 2024
Director at Shattuck Labs, Inc., and 3 other companies
SEC CIK 0001167496 · Filings on SEC.gov ↗
Clay B Siegall's record
3 months after each buy, from the first price a copier could get.
9 buys since 2024 with 3 months of prices.
Companies
Every filing
99 filings since Mar 2016, newest first
Shattuck Labs, Inc.
Director
Immunome Inc.
President and CEO
Immunome Inc.
President and CEO
Immunome Inc.
President and CEO
Immunome Inc.
President and CEO
Immunome Inc.
President and CEO
Immunome Inc.
President and CEO
Immunome Inc.
President and CEO
Immunome Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seagen Inc.
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Ultragenyx Pharmaceutical Inc.
Director
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
Insider
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
Seattle Genetics Inc /wa
President and CEO
About Clay B Siegall
Clay B. Siegall, Ph.D., is a biopharmaceutical executive and scientist who serves as a director of Shattuck Labs, Inc. (Nasdaq: STTK) and has recently reported open‑market purchases of Shattuck Labs stock as a corporate insider.( He joined Shattuck’s board of directors effective March 1, 2024, bringing extensive oncology drug-development and leadership experience to the clinical‑stage biotechnology company.( In a June 2026 underwritten offering, Siegall bought 62,500 shares of Shattuck Labs common stock at $4.00 per share, increasing his direct holdings to 318,608 shares.(
Siegall is the President, Chief Executive Officer, and Chairman of the Board of Immunome, Inc. (Nasdaq: IMNM), where he has led significant equity financings and oversees development of targeted oncology therapies.( He is best known as the founder and former CEO, president, and chairman of Seagen Inc. (formerly Seattle Genetics), which he co‑founded in 1998 and built into a leader in antibody‑drug conjugate (ADC) cancer therapies, including multiple FDA‑approved medicines.( Over a 25+ year career in the biopharmaceutical industry, he has also held senior or board roles at companies such as Morphimmune, Tourmaline Bio, Ultragenyx Pharmaceutical, and others.( A trained scientist, Siegall has authored more than 70 publications, holds numerous patents, and earned a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.